August 21, 2014 10:30 PM ET

Company Overview of Aclaris Therapeutics, Inc.

Company Overview

Aclaris Therapeutics, Inc. was incorporated in 2012 and is based in Malvern, Pennsylvania.

101 Lindenwood Drive

Suite 400

Malvern, PA 19355

United States

Founded in 2012



Key Executives for Aclaris Therapeutics, Inc.

Chief Executive Officer
Age: 44
Chief Financial Officer
Chief Operating Officer
Vice President of Clinical Operations
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Aclaris Therapeutics, Inc. Key Developments

Aclaris Therapeutics, Inc. Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis

Aclaris Therapeutics, Inc. announced positive results from a Phase 2 clinical trial of the company's drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses to have SK treated either because the lesions have become irritated or are cosmetically concerning. The double-blind, placebo-controlled Phase 2 clinical trial was designed to evaluate the safety, tolerability, and efficacy of A-101 in removing SK lesions. The trial used a within-subject design to compare three concentrations of A-101 and vehicle (placebo) in 35 patients with SK lesions. A-101 achieved statistical significance in clearing SK lesions on the back in a dose-related fashion. A-101 was well tolerated at all concentrations.

Aclaris Therapeutics, Inc. Announces Management Changes

Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, a board-certified dermatologist and experienced entrepreneur, will lead the company as Chief Executive Officer, President and Director. Dr. Walker has co-founded a number of life-science companies and brings more than eighteen years of pharmaceutical industry experience in research and development, regulatory affairs and business development to the company. Most recently, Dr. Walker served as Founder, CEO and Director of Vicept Therapeutics. Dr. Walker also co-founded Octagon Research Solutions, Inc. and served as its Director until August 2012. Stephen Tullman, the former Executive Chairman of Vicept, will serve as Chairman of the Board of Directors of the company. He currently serves as President and CEO of Ceptaris Therapeutics, Inc. In addition, he is Managing Partner of NeXeption. Albert Cha, M.D., Ph.D. and Ketan Patel, M.D. will join Mr. Tullman and Dr. Walker on the Board of Directors of the company. Dr. Cha is a managing partner at Vivo Ventures, where he invests in private and public biopharmaceutical and medical device companies. Dr. Patel is a principal with Fidelity Biosciences, where he focuses on investing in private life sciences companies globally.

Similar Private Companies By Industry

Company Name Region
Cordova Bancshares Inc United States
Halcon Operating Co., Inc. United States
Sarnova, Inc. United States
Polyconcept North America, Inc. United States
Wellbrook Finance LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aclaris Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at